Premium
[O4–03–03]: TREATMENT WITH CHOLINERGIC THERAPIES IN AD: RELATIONSHIP TO BRAIN STRUCTURE AND ATROPHY
Author(s) -
Hampel Harald
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.432
Subject(s) - basal forebrain , neuroscience , cholinergic neuron , cholinergic , neuroimaging , entorhinal cortex , atrophy , psychology , disease , hippocampus , neurology , alzheimer's disease , donepezil , pathology , dementia , medicine
amyloid positive at baseline, but 4 (12%) converted to amyloid positivity (SUVr> 1.10) at 27 months, leading to an 88% correct classification for amyloid negativity at 27 months. Conclusions: Identification of diminished cholinergic tone in at-risk CN adults, using the low-dose SCT, was predictive of amyloid positivity and decline in episodic memory 27 months later. Thus, this SCT may provide a minimally invasive screening method to rule-out cortical amyloid aggregation and cognitive decline, at least over a 27 month period. Such a screening test may help determine who should complete PETamyloid imaging. This study provides further evidence of the linkage between cholinergic deficits, amyloid pathology, and disease progression.